Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Hübschmann

Showing results (31-40 of 97) with videos related to

Pageof 10
Sort By:
Blood Advances|December 1, 2022
Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3AmutNPM1mut AMLsElisa Donato, Nadia Correia, Carolin Andresen, et al.
JCO Precision Oncology|July 2, 2025
Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in ChordomaDaniel S Lefler, Andrew Elliott, Wei Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2025
Precision oncology - Guideline of the Austrian, German and Swiss Societies for hematology and medical oncologyDamian T Rieke, Michael Bitzer, Annalen Bleckmann, et al.
NPJ Precision Oncology|December 15, 2025
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trialsFederico Nichetti, Jennifer Hüllein, Pauline du Rusquec, et al.
Cancer Treatment and Research Communications|September 11, 2025
Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trialChristoph E Heilig, Christoph Heining, Editha Gnutzmann, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|February 25, 2024
Evolution of SARS-CoV-2 in the Rhine-Neckar/Heidelberg Region 01/2021 - 07/2023Christian Bundschuh, Niklas Weidner, Julian Klein, et al.
Cold Spring Harbor Molecular Case Studies|December 1, 2016
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with <i>PDL1</i> amplificationStefan Gröschel, Martin Bommer, Barbara Hutter, et al.
Blood|December 21, 2018
The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphomaRabea Wagener, Julian Seufert, Francesco Raimondi, et al.
Cold Spring Harbor Molecular Case Studies|March 6, 2019
Response to olaparib in a <i>PALB2</i> germline mutated prostate cancer and genetic events associated with resistancePeter Horak, Joachim Weischenfeldt, Gunhild von Amsberg, et al.
European Journal of Endocrinology|June 1, 2023
Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort studyHanna Remde, Laura Schmidt-Pennington, Miriam Reuter, et al.
Pageof 10

Showing results (31-40 of 97) with videos related to

Sort By:
Pageof 10
Blood Advances|December 1, 2022
Retained functional normal and preleukemic HSCs at diagnosis are associated with good prognosis in DNMT3AmutNPM1mut AMLsElisa Donato, Nadia Correia, Carolin Andresen, et al.
JCO Precision Oncology|July 2, 2025
Pansarcoma Analysis of Cyclin-Dependent Kinase and Cyclin Outlier Gene Expression Highlights CDK7 as a Potential Therapeutic Target in ChordomaDaniel S Lefler, Andrew Elliott, Wei Jiang, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2025
Precision oncology - Guideline of the Austrian, German and Swiss Societies for hematology and medical oncologyDamian T Rieke, Michael Bitzer, Annalen Bleckmann, et al.
NPJ Precision Oncology|December 15, 2025
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trialsFederico Nichetti, Jennifer Hüllein, Pauline du Rusquec, et al.
Cancer Treatment and Research Communications|September 11, 2025
Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trialChristoph E Heilig, Christoph Heining, Editha Gnutzmann, et al.
Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases|February 25, 2024
Evolution of SARS-CoV-2 in the Rhine-Neckar/Heidelberg Region 01/2021 - 07/2023Christian Bundschuh, Niklas Weidner, Julian Klein, et al.
Cold Spring Harbor Molecular Case Studies|December 1, 2016
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with <i>PDL1</i> amplificationStefan Gröschel, Martin Bommer, Barbara Hutter, et al.
Blood|December 21, 2018
The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphomaRabea Wagener, Julian Seufert, Francesco Raimondi, et al.
Cold Spring Harbor Molecular Case Studies|March 6, 2019
Response to olaparib in a <i>PALB2</i> germline mutated prostate cancer and genetic events associated with resistancePeter Horak, Joachim Weischenfeldt, Gunhild von Amsberg, et al.
European Journal of Endocrinology|June 1, 2023
Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort studyHanna Remde, Laura Schmidt-Pennington, Miriam Reuter, et al.
Pageof 10